Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 13/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1279768 | 0.96 | TBXA2R (0.43) | TBXA2RMCHR1SSTR4CHRM4KMT2A | |
| Hydrochloric Acid SCHEMBL1280031 | 0.95 | TBXA2R (0.43) | TBXA2RMCHR1SSTR4CHRM4KMT2A | |
| SCHEMBL12253145 | 0.94 | TBXA2R (0.43) | TBXA2RMCHR1SSTR4CHRM4KMT2A | |
| SCHEMBL12253141 | 0.94 | TBXA2R (0.43) | TBXA2RMCHR1KMT2A | |
| Sulfuric Acid SCHEMBL1279083 | 0.94 | TBXA2R (0.44) | TBXA2RMCHR1SSTR4CHRM4KMT2A | |
| SCHEMBL1279738 | 0.94 | TBXA2R (0.44) | TBXA2RMCHR1SSTR4CHRM4KMT2A | |
| SCHEMBL12253139 | 0.94 | TBXA2R (0.42) | TBXA2RMCHR1CHRM4KMT2ANR2F2 | |
| SCHEMBL12253144 | 0.94 | TBXA2R (0.42) | TBXA2RMCHR1CHRM4KMT2ANR2F2 | |
| SCHEMBL12253099 | 0.93 | TBXA2R (0.42) | TBXA2RMCHR1KMT2A | |
| Phosphoric Acid SCHEMBL1279887 | 0.93 | TBXA2R (0.41) | TBXA2RSSTR4CHRM4KMT2ACACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221428-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8741894-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20110230487-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230487-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | TBXA2R 2704/4885MCHR1 541/4885SSTR4 2979/4885 |
| US-20140221428-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | TBXA2R 2704/4885MCHR1 541/4885SSTR4 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.